.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX17_SacituzumabGovitecan.SacituzumabGovitecan .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX17_SacituzumabGovitecan.SacituzumabGovitecan| name: | SacituzumabGovitecan |
| ATC code: | L01FX17 | route: | intravenous |
| n-compartments | 2 |
Sacituzumab govitecan is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting Trop-2, linked to the cytotoxic agent SN-38, an active metabolite of irinotecan. It is used for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. It is FDA and EMA approved for this indication.
Pharmacokinetic parameters of sacituzumab govitecan (the antibody-drug conjugate, not unconjugated SN-38) in patients with advanced solid tumors as reported in adult females and non-small cell lung cancer patients after intravenous administration.
Sathe, AG, et al., & Othman, AA (2024). Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. Clinical pharmacokinetics 63(5) 669–681. DOI:10.1007/s40262-024-01366-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38578394
Bardia, A, et al., & Ocean, AJ (2021). Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Annals of oncology : official journal of the European Society for Medical Oncology 32(6) 746–756. DOI:10.1016/j.annonc.2021.03.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33741442